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Abstract
Background: Breast cancer is one of the most important neoplasia among women. It was recently suggested that
biological agents could be the etiological cause, particularly Human Papilloma Virus (HPV). The aim of this study
was to explore the presence of HPV DNA in a case-control study.
Methods: We performed our study including 251 cases (breast cancer) and 186 controls (benign breast tumors),
using three different molecular techniques with PCR (GP5/GP6, CLART® and DIRECT FLOW CHIP®).
Results: HPV DNA was evidenced in 51.8% of the cases and in 26.3% of the controls (p < 0.001). HPV-16 was the
most prevalent serotype. The odds ratio (OR) of HPV within a multivariate model, taking into account age and
breastfeeding, was 4.034.
Conclusions: Our study, with methodological rigour and a sample size not previously found in the literature,
demonstrate a significant presence of HPV DNA in breast cancer samples. A possible causal relationship, or
mediation or not as a cofactor, remains to be established by future studies.
Keywords: Breast cancer, Human papillomavirus, Prevalence, PCR
Background
Breast cancer is the most commonly diagnosed malig-
nancy in women [1–3]. It is estimated that 1.7 million
new cases were diagnosed in 2012, representing 11.9% of
all cancers diagnosed worldwide in both genders, and
25% of those diagnosed in women [3, 4]. Breast cancer is
also the most common malignancy in Spanish women,
representing 29% of all female malignancies. Most of the
cases are diagnosed in patients between 45 and 65 years
of age [5].
Several risk factors have been cited in the literature,
including patient age, gender, hormone therapy, the
number of offspring, breastfeeding or different eating
habits. However, there are other less well known factors
that might also play an oncogenic role. Viruses are an
example in this respect [6]. A number of viruses have
been identified to date in breast cancer tissues. The
three main viruses are Epstein Barr virus (EBV), mouse
mammary tumor virus (MMTV) and human papilloma-
virus (HPV) [7–11]. All of them share a common feature
in that they can induce the initiation and progression of
cancer. Several studies [8, 9, 12–19] have attempted to
determine whether viruses in breast tissue are a casual
presence (i.e., acting as “passengers”) or they play an im-
portant role in carcinogenesis. The fact is that with the
exception of MMTV, the rest of the viruses described in
breast cancer have already been identified in other ma-
lignancies. The current published data on HPV and
breast cancer are very contradictory, since the reported
prevalence of HPV ranges from 0% [20–29] to 86.21% in
breast cancer tissue samples [8, 10, 30–35]. Furthermore,
the studies are very heterogeneous in terms of the meth-
odology employed. A example of this is that, most of the
reviewed studies involve case studies without controls. A
few use case-control protocols, which offer greater
methodological soundness, while only a handful evaluate
statistically significant differences [9, 31, 36–43]. More-
over, the only study conducting logistic regression is that
published by Sigaroodi et al. [40], though it involves a
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very wide confidence interval (1.5–130) and odds ratio
[OR] = 14, which is questionable in statistical terms.
In view of the above, the investigation of viruses as
breast cancer promoting factors remains subject to great
controversy. The present study was designed to help
clarify this issue. Specifically, we aimed to confirm the
presence of HPV in a series of samples obtained from
breast surgeries at the University General Hospital of
Alicante (Spain), estimating the strength of the associ-
ation (via [OR]) between the presence of HPV in benign
breast disease and breast cancer.
Methods
A case-control study, based on a case-control ratio of
1:1, was performed to evaluate the presence of HPV in-
fection in a subset of 250 embedded breast cancer
tissues, as cases, and 250 embedded benign breast
tissues, as controls. The estimated exposure rate (pres-
ence of HPV) was 25% and 14% in the cases and con-
trols, respectively, with a confidence level of 95% and a
statistical power of 85% in detecting OR >2 (computed
pooling proportions of reviews or meta-analyses pub-
lished until 2012) [8, 30, 32]. The samples were selected
consecutively and retrospectively from the year 2012
until the calculated sample size (n) was reached. The
following inclusion criteria were established: women
subjected to surgical treatment due to infiltrating breast
cancer and/or carcinoma in situ (cases) or benign breast
disease (controls) (period 2006–2012); patients over
18 years of age; surgical specimens embedded in paraffin
(stored in the tumor Biobank of our institution), in ad-
equate conditions and sufficient amount of tissue for
the purposes of the study; and the obtainment of writ-
ten informed consent. The following exclusion criteria
were established: males and a lack of the minimum
required quality controls in the analyzed DNA samples.
An ad-hoc case report form was created to record
demographic, histopathological and virological informa-
tion. Data were anonymized in compliance with the
protection of personal data code.
Immunohistochemical and in SITU hybridization analysis
After surgical excision (either mastectomy or tumorect-
omy), specimens were fixed in 10% formalin solution
and subsequently embedded in paraffin. For the histo-
logical study, sections measuring 4 μm in thickness were
obtained and stained with hematoxylin-eosin. The
expressions of estrogen receptor (ER), progesterone re-
ceptor (PgR), human epidermal growth factor receptor
(HER2) and Ki-67 were determined by immunohisto-
chemistry (IHC) using standard techniques, with com-
mercial antibodies and conditions following the
instructions of the manufacturer on an automated basis
(Techmate-500). The following antibodies were used: ER
(Dako, clone 1D5, dilution 1:50), PgR (Dako, clone PgR
636, dilution 1:50), Ki-67 (Dako, clone MIB-1, dilution
1:100) and HercepTest® (Dako). The study of the ER and
PR expression levels was made evaluating the percentage
of stained tumor cell nuclei and the intensity of staining
according to the guidelines of the American Society of
Clinical Oncology (2010) [44] and of the American
College of Pathologists. Positive status was considered
for >1% ER or PR. HER2 status in turn was determined
according to the recommendations of the American
Society of Clinical Oncology (2007) and guidelines of
the American College of Pathologists [45]. Immunohis-
tochemical positive was defined as staining 3+ (uni-
form, membrane staining intensity >10% of the
infiltrating tumor cells), while negative was defined as
staining 0 or 1+. ERBB2 gene status was confirmed by
fluorescence in situ hybridization (FISH) (Dako phar-
maDx™) or chromogenic in situ hybridization (CISH)
(Spot light™; Zymed) in equivocal cases (2+ and <10% 3+
cells). Ki67 was semiquantitatively assessed in at least
three high-magnification fields [×400] including hot-spots
areas, and classified as low (<14%) versus high (>14%) (nu-
clei) [44, 45].
Viral DNA sequences extraction
The search for viral DNA was carried out at the Instituto
de Estudios Celulares y Moleculares (Lugo, Spain), due to
its well demonstrated experience in molecular and genetic
studies. Sections measuring 10 μm in thickness were ob-
tained from the tumor area of the paraffin block for the
identification of viral DNA. In order to avoid cross-
contamination between samples, special care was taken in
handling and sectioning the samples. The following pro-
cedure was carried out:
1. Deparaffinization: Four paraffin-embedded tissue
sections were placed in a 1.5-ml tube, followed by
the addition of 1 ml of xylene and vortexing for 10 s.
After incubation at room temperature during
10 min, centrifugation was carried out at 13,000 rpm
for 5 min. The supernatant was discarded and 1 ml
of absolute ethanol was added, followed by centrifu-
gation at 13,000 rpm for 2 min. The supernatant
was then again discarded. This ethanol washing step
was repeated one more time. Lastly, the sample was
incubated at 56 °C during 15 min to eliminate the
traces of ethanol.
2. DNA extraction: After completion of the
deparaffinization process we added 500 μl of lysis
buffer (10 mM Tris pH 8, 100 mM NaCl, 25 mM
EDTA, 0.5% sodium dodecylsulfate [SDS]) and 10 μl
of proteinase K (20 mg/ml), followed by vortexing
and incubation in a shaking water bath at 56 °C
overnight. Proteinase K was inactivated by
Delgado-García et al. BMC Cancer  (2017) 17:320 Page 2 of 11
incubation at 95 °C during 10 min. An equivalent
volume of chloroform: isoamyl alcohol (24:1 v/v)
was added, shaking gently by inverting the tube
and then centrifuging at 10,000 rpm for 10 min.
The upper aqueous phase was transferred to a new
microcentrifugation tube, and 0.2 volumes of
ammonium acetate 10 M were added. The DNA
was precipitated by adding two volumes of absolute
ethanol, followed by vortexing for 5 s, incubation at
−20 °C during 30 min and centrifugation at
10,000 rpm for 20 min. The supernatant was
discarded and the precipitate was washed with
500 μl of cold 70% ethanol, followed by
centrifugation for 5 min at 10,000 rpm. After
discarding the supernatant again, the precipitate
was dried at room temperature during 20 min.
The DNA was finally resuspended in 50 μl of
Tris-EDTA solution.
3. Amount and quality of DNA: All DNA samples
were analyzed using a Nanodrop 1000 kit allowing
calculation of the concentration of DNA and the
A260/A280 and A260/A230 ratios, which indicate
the purity of the molecule.
4. DNA amplification capacity: The integrity of the
extracted DNA was evaluated by polymerase chain
reaction (PCR) amplification of a fragment of the
methylenetetrahydrofolate reductase (MTHFR) gene.
5. Detection and genotyping of HPV: The samples
were subjected to three different HPV detection
methods:
1. - Amplification of the virus using the GP5+/GP6+
consensus primers: The presence of HPV DNA
was evaluated by PCR using the GP5+/GP6+
primers (150 bp), which act as consensus primers
for the HPV L1 gene. The PCR reaction was carried
out with 5 μl of DNA in a total reaction volume
of 50 μl containing 25 μl of DreamTaq Green PCR
Master Mix 2X (ThermoFisher Scientific), 1 μM of
each primer, 0.2 mM of DNTPs and 2 mM of
MgCl2. Amplification was performed with initial
activation of the enzyme at 95 °C during two
minutes, followed by 45 cycles under the following
conditions: 30 s at 95 °C, two minutes at 40 °C and
1.5 min at 72 °C, with a final elongation step at
72 °C during 5 min. The PCR products were
visualized in 2% agarose gel with ethidium bromide
staining using electrophoresis.
2. - CLART® HPV2 amplification kit (Genomica): This
kit detects the presence of the 35 HPV viruses: 6, 11,
16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81,
82, 83, 84, 85 and 89. Detection is carried out
through amplification of a fragment of about 450 bp
within the L1 region of the virus. Five μl of DNA of
each sample were subjected to PCR assay using the
CLART HPV2 amplification kit (Genomica): one
cycle at 95 °C for 5 min, 40 cycles at 94 °C for 30 s/
55 °C for 60 s / 72 °C for 90 s, and one cycle at
72 °C for 8 min. The PCR products were
denaturalized at 95 °C during 10 min and placed
in a container with ice. Hybridization was performed
using 10 μl of the denaturalized PCR product in
the CLART microarray, followed by examination
according to the instructions of the manufacturer.
3. - HPV Direct Flow CHIP kit (Master Diagnostica):
The technique is based on amplification of the viral
DNA followed by membrane flow-through reverse
dot blot hybridization of the amplified products.
Types of HPV detected: High oncogenic risk
(16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 73 and 82) and low oncogenic risk (6, 11, 40,
42, 43, 44, 54, 55, 61, 62, 67, 69, 70, 71, 72, 81, 84
and 89 (CP6108)). Six μl of purified DNA of each
sample were amplified by PCR under the following
conditions: one cycle at 98 °C for 5 min, 5 cycles at
98 °C for 5 s / 42 °C for 5 s / 72 °C for 10 s, 45 cycles
at 98 °C for 5 s / 60 °C for 5 s / 72 °C for 10 s, and
one cycle at 72 °C for one minute. The samples were
kept in refrigerated tubes (8–10 °C) until processing.
The PCR products were denaturalized by heating to
95 °C for 5 min (in a thermocycler) and then quickly
cooled in ice for two minutes.
Hybridization and interpretation of the results were
carried out following the instructions of the kit manufac-
turer. All samples were analyzed using the three tech-
niques above mentioned to increase test sensitivity. A
positive result was defined when at least two of the three
methods detected the presence of HPV. If the results
proved questionable, or in the event of insufficient ma-
terial, the sample was discarded to the effects of analysis.
Likewise, all the samples passed the cellular DNA test
(internal control), to avoid possible false-negative results.
As negative control we included “HPV free DNA” and as
positive control a HPV plasmid mixture with all target
types. Contradictory results were obtained in only 6
samples, and these were therefore considered lost.
The following variables were recorded: patient age, per-
sonal breast cancer history, smoker, number of children,
breastfeeding, age at menopause, history of cervical disease,
adjuvant therapy, histopathological of the tumor (tumor
size, grade, stage, number of positive lymph nodes, local/
distant metastasis), immunohistochemical characteristics
(ER, PgR, HER2, Ki67), and the detected HPV serotype.
Data analysis
A descriptive analysis was made of all the study vari-
ables. In order to analyze the homogeneity of the two
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groups (cases and controls) with respect to those vari-
ables which the literature describes as being associated
to breast cancer, a calculation was made of the means of
the quantitative variables for both groups and compari-
sons were established using the Student t-test. In the
case of the qualitative variables, cross tables were gener-
ated, and associations were analyzed using the Chi-
Squared test. In addition, any variables (qualitative or
quantitative) found to be non-homogeneous in the cases
and controls were taken into account when explaining
the lack of homogeneity for the other variables. To this
effect, we calculated the strength of the association be-
tween the cases and controls with the variable in ques-
tion, in the presence of those variables which had
already demonstrated a lack of homogeneity in both
groups. This process was carried out using a binary lo-
gistic regression model. In order to establish the associ-
ation between HPV exposure and breast cancer, we
generated a cross tables between the two variables, esti-
mating the magnitude of the association based on calcu-
lation of the raw odds ratio (OR) for the development of
breast cancer. In addition, we calculated the adjusted
OR by binary logistic regression, with the corresponding
95% confidence interval (CI). A p-value <0.05 was con-
sidered statistically significant. Statistical analysis was
carried out using the software package SPSS version 20.
Results
The final study included 437 samples: 251 cases (57.4%)
and 186 controls (42.6%). (Table 1).
The mean age of the cases (n = 251) was 56.3 years,
versus 40.1 years for the controls (n = 186) ((p < 0.001).
Of note, the two groups are not homogeneous. A statis-
tically significant difference of 16 years was observed be-
tween the cases and controls (Tables 1 and 2). This is
justified on the basis of the natural courses of breast
cancer and benign disease, and the curves corresponding
to breast cancer and benign disease by ages described by
the World Health Organization (WHO) [4] are analo-
gous to those of our own study. Clearly, for ethical rea-
sons, we cannot obtain healthy tissues on a random
basis from health women without breast disease. Selec-
tion bias results if the groups are not homogeneous.
However, by using statistical tools such as binary logistic
regression analysis, we can control this bias referring to
the lack of homogeneity in terms of variables which pre-
sumably may be related to cancer. Furthermore, this
statistical tool allows us to calculate odds ratios for each
variable. After justification of the variable age, we com-
pared the rest of the variables of the cases and controls
(Table 2), and these were found to be homogeneous after
logistic regression adjustment to age. This allows us to
establish statistical comparisons of our primary variable,
which is the presence or not of viral DNA.
Data obtained to determine the presence of HPV in
breast cancer tissue samples and establish the compari-
son with the samples corresponding to benign breast tis-
sue, were analyzed using the Chi-Squared test. Using
this test, the HPV exposure rate among the cases was
significantly higher (51.8%) than the HPV exposure rate
in the controls (26.3%) (p < 0.001) (Table 3).
The raw OR was 3.0 (CI 95%: 2.0–4.5). On applying
the binary logistic regression model to control for con-
founding variables, the OR assigned to HPV was seen to
be 4.034 (CI 95%: 2.213–7.352) (Table 4), which means a
higher risk of suffering cancer in the presence of HPV,
taking into account patient age and breastfeeding. The
rest of the confounding variables showed no significance
in the binary logistic regression model (all p = non
significant).
The mean tumor size in HPV-positive tumors was
larger (30.53 mm) than in those HPV-negative
(28.37 mm), though the difference failed to reach statis-
tical significance (p = 0.395). None of the analyzed
histopathological variables showed a statistically signifi-
cant association with the presence of HPV (Table 5, at
the end).
Regarding the association of the different immunohis-
tochemical subtypes with the presence or not of HPV,
the presence of HPV is related to the luminal B pheno-
types (particularly HER2-negative), while in contrast the
triple negative and luminal A phenotypes are more re-
lated to the absence of HPV. However, this relationship
is not statistically significant (p = 0.055) (Table 5).
Within the global sample, 47% of the cases (n = 55)
and 61.2% of the controls (n = 30) were infected by
Table 1 Clinical characteristics of breast cancer tissues (cases) and breast benign diseases (controls)
Cases Controls
N Mean (CI 95%) N Mean (CI 95%)
Age** 251 56.32 (54.76–57.88) 186 40.08 (38.3–41.86)
Number of children 250 1.92 (1.76–2.09) 185 1.3 (1.11–1.5)
Breastfeeding duration (months) 191 8.65 (7.16–10.15) 115 9.42 (6.92–11.92)
Age at menopause 140 48.89 (48.16–49.61) 36 48 (46.47–49.53)
Tumor size (mm) 249 29.49 (26.99–31.99) 98 31.83 (29.31–34.34)
CI 95% Confidence Interval 95%, ** Statistic Signification <0.01
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more than one HPV serotype. In other words, co-
infection by more than one viral serotype was observed
in 85 samples. With regard to the identified serotypes, in
the 179 samples (130 cases and 49 controls) with the
presence of viral DNA, we identified 16 different high
risk serotypes and 11 low risk serotypes. Figures 1 and 2
show HPV serotype 16 to be the most frequent high risk
serotype in both the cases and the controls, followed by
HPV-89 (Fig. 3).
Discussion
Band in 1991 [46] were the first to postulate that HPV
might be implicated in breast cancer. These authors sug-
gested that HPV-16/HPV-18 could immortalize the
epithelial cells of normal mammary gland tissue through
the inhibition of apoptosis. Shortly after, in 1992, Di
Lonardo [47] by PCR techniques confirmed the presence
of HPV-16 in 29.4% of 17 breast cancer samples sup-
porting a potential relationship between HPV and breast
carcinoma.
In the current study, the presence of HPV was shown
in 51.8% of the cases and 26.3% of the controls. Of note,
these results are higher than the prevalence described by
some meta-analyses [30], in which HPV was found to be
present in 23% of the cases and in 12.9% of the controls,
although the difference here was also statistically
Table 2 Frequency of cases and controls by clinicopathological factors
Number Cases n (%) Controls n (%) p-value
(p-value adjusting for age)
OR (CI 95%) AOR by Age (CI 95%)
Age (years) < 40 109 19 (7.6) 90 (48.4) <0.001 1 −
40–49 119 60 (23.9) 59 (31.7) 4.8 (2.6–8.9)** −
50–59 97 72 (28.7) 25 (13.4) 13.6 (7.0–26.7)** −
≥ 60 112 100 (39.8) 12 (6.5) 39.5(18.2–85.8)** −
Smoker Yes 196 93 (37.7) 103 (56.3) <0.001
(0.446)
0.5 (0.3–0.7)** 0.8(0.5–1.2)
No 234 154 (62.3) 80 (43.7) 1 1
Personal BC history Yes 13 12 (4.8) 1 (0.5) 0.009
(0.086)
9.3 (1.2–72.1)** 7.0(0.8–64.7)
No 424 239 (95.2) 185 (99.5) 1 1
Number of children 1+ 326 205 (81.7) 121 (65.1) <0.001
(0.465)
2.4 (1.5–3.7)** 1.0 (0.6–1.8)
None 111 46 (18.3) 65 (34.9) 1 1
Breastfeeding (months) 12+ 81 52 (27.2) 29 (25.2) 0.789
(0.139)
1.1 (0.6–1.9) 0.8 (0.4–1.5)
0–11 170 139 (72.8) 86 (74.8) 1 1
Menopausial status Yes 188 152 (62.0) 36 (19.7) <0.001
(0.238)
6.7 (4.2–10.4)** 0.7 (0.3–1.6)
No 240 93 (38.0) 147 (80.3) 1 1
Age at menopause (years) ≥ 54 25 24 (15.8) 1(2.8) 0.012
(0.179)
18 (1.9–173)** 7.5 (0.7–82.6)
42–53 149 120 (78.9) 29 (80.6)* 3.1 (0.9–9.6)* 1.8 (0.5–6.9)
≤ 41 14 8(5.3) 6 (16.7) 1 1
History of cervical diseases No 302 156 (95.7) 146 (91.8) 0.171
(0.288)
1.9 (0.8–5.1) 1.7 (0.6–4.8)
Yes 20 7 (4.3) 13 (8.2) 1 1
OR Odd Ratio, AOR Adjusted Odd Ratio, BC Breast Cancer, CI 95% Confidence Interval 95%, * Statistic signification <0.05, ** Statistic Signification <0.01
Table 3 Frequency of HPV-positive by cases and controls
Cases (n = 251) Controls (n = 186) OR (CI
95%)N % N %
HPV HPV+ 130 51.8% 49 26.3% 3.0 **
HPV- 121 48.2% 137 73.7% (2.0–4.5)
** Statistic Signification <0.01, CI 95% Confidence Interval 95%
Table 4 Binary logistic regression model to control for
confounding variables in a case-control study
Coef. B Sig. OR. CI. 95%
HPV 1.395 <0.001 4.034 2.213–7.352
Age 0.11 <0.001 1.116 1.084–1.15
Breastfeeding −0.032 0.022 0.969 0.943–0.996
Constant −5.274 <0.001 0.005
Coef. B. Value of the coefficient in the logistic regression model. Sig Statistic
signification, OR Odd Ratio, CI 95% Confidence Interval 95%
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significant. Nevertheless, it should be mentioned that
there is a broad range of HPV-positive findings in
breast cancer samples, depending on the geographical
setting involved. In fact, according to Simoes [30], the
prevalence in Europe is 13.4%, versus 42.9% in
Australia and North America. The OR calculated by
this author showed HPV-positive women to have a 5.9
fold higher risk of suffering breast cancer than HPV-
negative women (95%CI: 3.36–10.67). The OR in our
study was 4.034 (95% CI: 2.213–7.352), i.e., somewhat
lower than in the above study.
Regarding the implications of the presence of HPV in
benign disease (26.3% in this study), our hypothesis is
that if we follow the pattern of cervical cancer and HPV,
and if HPV is considered to be oncogenic for breast can-
cer, then it should be present both in this tissue and in
some normal breasts or breasts with precancerous le-
sions (supposedly in lesser proportion).
In 2004, De Villiers [35] published the highest preva-
lence to date. She detected HPV in 86% of the cases (25/
29 breast cancers) and in 69% of the nipple tissue sam-
ples of the same breasts used as controls (20/29). Other
Table 5 Frequency of HPV-positive cases (Breast cancer) by clinicopathological factors
Number HPV+ HPV- P* OR (CI 95%)
n % n %
Lymph vascular invasion Yes 43 23 17.7% 20 16.5% 0.868 1.1 (0.6–2.1)
No 208 107 82.3% 101 83.5% 1
Lymph node metastasis Yes 104 52 40.0% 52 43.0% 0.701 0.9 (0.5–1.5)
No 147 78 60.0% 69 57.0% 1
Metastasis Yes 10 6 4.6% 4 3.3% 0.751 1.4 (0.4–5.1)
No 241 124 95.4% 117 96.7% 1
Neoadjuvant therapy Yes 33 16 12.3% 17 14.0% 0.712 0.9 (0.4–1.8)
No 218 114 87.7% 104 86.0% 1
Stage 0 25 14 10.9% 11 9.3% 0.724 1
IA 51 30 23.4% 21 17.8% 1.1 (0.4–2.9)
IB 1 1 0.8% 0 0.0% …
IIA 78 35 27.3% 43 36.4% 0.6 (0.3–1.6)
IIB 45 25 19.5% 20 16.9% 1.0 (0.4–2.6)
IIIA 32 15 11.7% 17 14.4% 0.7 (0.2–2.0)
IIIC 3 2 1.6% 1 0.8% 1.6 (0.1–20.0)
IV 11 6 4.7% 5 4.2% 0.9 (0.2–3.9)
ER 0 39 18 14.1% 21 17.5% 0.407 2.6 (0.2–27.0)
1–19% 4 1 0.8% 3 2.5% 1
≥20% 205 109 85.2% 96 80.0% 3.4 (0.3–33.1)
PgR 0 51 26 20.3% 25 20.8% 0.581 0.7 (0.3–1.7)
1–19% 37 22 17.2% 15 12.5% 1
≥20% 160 80 62.5% 80 66.7% 0.7 (0.3–1.4)
HER2 + 43 27 21.3% 16 13.8% 0.134 1.7 (0.9–3.3)
− 200 100 78.7% 100 86.2% 1
Ki-67 < 14 84 37 28.9% 47 39.5% 0.083 1
14–19* 71 44 34.4% 27 22.7% 2.1 (1.1–3.9)
≥ 20 91 47 36.7% 45 37.8% 1.4 (0.7–2.5)
Immunohisto-chemical subtypes LUMINAL A 88 37 29.4% 51 44.0% 0.055 1.2 (0.4–4.0)
LUMINAL B/HER2- 83 50 39.7% 33 28.4% 2.1 (0.6–7.1)
LUMINAL B/HER2+ 35 23 18.3% 12 10.3% 2.7 (0.7–10.4)
HER2+ 12 5 4.0% 7 6.0% 1
TRIPLE NEGATIVE 24 11 8.7% 13 11.2% 1.2 (0.3–4.8)
ER. PgR, HER2 OR Odd Ratio, CI 95% Confidence Interval 95%, * Statistic Signification <0.05
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authors [38] have also used the same cancer-affected
breast as control. However, in our opinion the use of
these controls is questionable from a methodological
perspective, since the breasts involved presented cancer
and were, therefore, not normal. Most of the published
studies do not follow a precise methodology, and the
screening criteria used are very heterogeneous. Some
studies only consider juvenile malignancies [34], while
others include inflammatory breast cancer tissues [48,
49], triple-negative tumors [50], medullary malignancies
[51], metaplastic breast cancer [52], papillary lesions [20,
53], Paget’s disease [54], or carcinoma in situ [9, 24, 25,
36, 41, 55–60]. In addition, no standards are used in
selecting the molecular technique to screen for viruses,
implying the potential detection of different viral sero-
types. Therefore, it is quite likely that, discrepancies
among the studies are due to the factors mentioned
above.
The literature published to date describes the presence
of both oncological high and low risk HPV serotypes,
with a broad variety of HPV subtypes. Even cutaneous
variants have been reported, as in the studies of De
Villiers [61] or Ong [62], who found HPV-27 or −57,
and HPV-4, respectively. Our data are consistent with
the findings in the literature, according to which HPV-
16 is the most frequently identified serotype. However,
in our study a low risk serotype not previously reported
was identified, and moreover was the most prevalent
among all the cases: serotype HPV-89 (Fig. 2). A possible
explanation for this observations is that we used differ-
ent detection methods in order to increase the range of
our findings.
On the other hand, in all published studies which in-
clude cases and controls, the prevalence of HPV has
been found to be higher in the cases than in the con-
trols. In contrast, Wang et al. [63] identified HPV in one
sample of 7 breast cancers and in two benign disease
samples. Obviously, this study presents clear limitations
in terms of sample size. Most of the published articles
lack a rigorous methodological design in relation to the
calculation of sample size, a fact that can weaken the re-
sults obtained. In our study, the case and control groups
were designed on a 1:1 basis, and although we finally in-
cluded 251 cases and 186 controls (i.e., a precise 1:1 pro-
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Fig. 2 Percentage of low risk (LR) viral serotypes. Percentage of low risk (LR) viral serotypes with respect to total sample size
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To our knowledge, our study includes the larger series
of samples in which HPV has been analyzed by three dif-
ferent validated molecular methods. Recent studies by Li
et al. [64] (including 187 breast cancers and 92 benign
tumors) and by Fu et al. [43] (with 169 cases and 83
controls) both in China, have shown that HPV may have
a possible causal role in breast cancer pathogenesis
[65, 66] It could be concluded that demographic and
genetic characteristics may be determinant in HPV-
positive breast cancer, in view of the wide range of
results obtained. This is a possible explanation be-
cause there is such a different prevalence.
In our study, the presence of HPV was associated
(but not significant p value, p = 0.055) to luminal B-
HER2-negative immunophenotype. This observation is
consistent with high Ki-67 levels, since luminal B
tumors present at least intermediate or high Ki-67
expression. In this respect, among HPV-positive tu-
mors, about 40% were luminal B/HER2-negative. In this
regard, El-Shinawi et al. [49] found the expression of
Ki-67 significantly higher in both (inflammatory and
non-inflammatory) breast cancer with viral DNAs. In
contrast, Subhawong in 2009 [67] established a similarity
between the immunophenotypic characteristics of triple-
negative tumors (and more specifically of basal-like
tumors) and HPV-positive squamous cell carcinomas
(functional loss of the retinoblastoma tumor suppressor,
presence of p16 or p53 overexpression). However, in that
study of 33 triple-negative breast cancers, no viral DNA
was identified by in situ hybridization techniques. Other
authors [48, 50] have also reported significant differences
with triple-negative tumors. Recently, in 2015, Fernandes
et al. [60] found no statistically significant association be-
tween the molecular subtypes and the presence of HPV;
however the sample size was very small (10 HPV-positive
samples out of a total of 24).
It is well known that luminal B tumors are ER-
dependent neoplasms, a condition which in turn favors
the perpetuation of cervical HPV infection. Therefore,
further studies are needed to confirm our results.
Emphasis should be placed on the importance of fur-
ther studies to clarify the role of HPV in the carcino-
genic mechanisms in breast cancer. First to clarify
whether causal relationship between the virus and breast
cancer actually exists. Human papillomavirus can be
transmitted by skin-to-skin contact, as well as by sexual
activity. Sexual transmission is the generally accepted
transmission route, though it is not the only route, since
transmission could occur by hand from the female peri-
neum to the breast, wich could occur during sexual ac-
tivity or even showering or bathing [8, 11, 68–70]. In an
attempt to identify the possible origin of HPV in the
breast, a number of authors [71–74] have explored the
possible relationship between presence of the virus in
the breast and cervical disease produced by HPV. Based
on their studies it is not possible to conclude that HPV
of the breast originates from the cervix. Further research
is needed. On the other hand, De Villiers et al. [61] dem-
onstrated the presence of HPV in 69% of the nipples of
breasts with cancer. This as early as 2004 already sug-
gested that HPV could gain access to the breast tissues
through the nipple. Based on this idea, some investiga-
tors postulated breast milk as one of the main transmis-
sion routes of the virus, with the breast epithelial cells as
the site of latent infection [9, 10].
Accordingly, breast epithelial cells that lose cell prolif-
eration control are more susceptible to HPV infection.
This loss of control is one of the first steps in breast car-
cinogenesis. Human papillomavirus infection in women
takes place through contact by the hands or body fluids
(e.g. breast milk...), with microfissures in the nipple serv-
ing as entry points for HPV. Errors may occur in the
normal cell repair process, and this in combination with
other cofactors can favour cell immortalization. Some of
these immortal cells can be infected with viral DNA epi-
somes or integrated DNA. The possible mechanisms
whereby HPV intervenes in breast carcinogenesis may
be the same as in the anogenital setting [42], through E6
and E7, though the viral load found in the breast is
much lower.
The presence of HPV might also provide a new target
allowing individualized patient treatment. The possibility
of including antiviral agents as part of the strategy for
the prevention (vaccines) [18, 75] and treatment of
breast cancer could be a reality in the future, as it is cur-
rently done in other cancers, such as hepatocellular car-
cinoma or Kaposi’s sarcoma.
In contrast to other viruses with known neoplastic
transformation potential, HPV can be defined as having
“indirect” oncogenic capacity. The so-called “viral trans-
forming genes”, which synthesize proteins involved in
the inhibition and degradation of key mediators in cell
division and the control of apoptosis (p53 and Rb), pro-
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Fig. 3 Proportion of viral serotypes found more frequently in
this study
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due to the impossibility of repairing DNA errors induced
by a series of intrinsic or extrinsic factors during cell
division. The oncogenic action is therefore indirect,
since there is no direct intervention as host gene pro-
moters, regulators or inhibitors. Oncogenic papilloma-
viruses intervene in the cell division phase, promoting
inhibition of the cellular repair capacity. This
phenomenon, and the associated environmental
circumstances, lead to the accumulation of errors,
often acquired on a random basis (so called clasto-
genic effect), with a phenotype that is independent of
the initial presence of the virus. No differences would
therefore be expected in the phenotypic evolution of
tumors induced by HPV or potentially induced by
some other type of genetic-environmental event.
Conclusions
In conclusion, this study of 251 cases and 186 controls
has evidenced HPV DNA in 51.8% of the cases (breast
cancer specimens) and in 26.3% of the controls (benign
disease). Furthermore, the OR corresponding to HPV
within the multivariate model, taking age and lactation
into account, is 4.034. We have not been able to establish
a significant relationship between the presence of viral
DNA and the immunohistochemical subtypes. Neverthe-
less, there is a certain tendency to correlate the presence
of HPV to the HER2- luminal B subtype (p = 0.055). In
concordance with existing literature, the most prevalent
serotype was found to be HPV-16. The strongly discrepant
results in the literature are explained by the great meth-
odological diversity found among the different studies.
Our study, with methodological rigour and a sample size
not previously found in the literature, demonstrate a sig-
nificant presence of HPV DNA in the breast cancer sam-
ples. A possible causal relationship, or mediation or not as
a cofactor, remains to be established by future studies.
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